Versant Venture Management LLC maintained its position in OpGen, Inc. (NASDAQ:OPGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,554,211 shares of the medical research company’s stock at the end of the second quarter. OpGen makes up 1.3% of Versant Venture Management LLC’s portfolio, making the stock its 8th largest position. Versant Venture Management LLC owned approximately 0.09% of OpGen worth $1,647,000 as of its most recent filing with the SEC.

OpGen, Inc. (NASDAQ OPGN) opened at 0.2722 on Friday. The stock’s 50 day moving average price is $0.43 and its 200-day moving average price is $0.83. OpGen, Inc. has a 52 week low of $0.26 and a 52 week high of $3.10. The company’s market capitalization is $14.03 million.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at

A number of research analysts recently commented on OPGN shares. Dawson James reissued a “buy” rating on shares of OpGen in a research note on Monday, June 19th. HC Wainwright set a $1.00 target price on OpGen and gave the company a “buy” rating in a research note on Wednesday. Finally, Zacks Investment Research raised OpGen from a “sell” rating to a “hold” rating in a research note on Wednesday, June 28th.

In other news, Chairman Jven Capital, Llc purchased 1,875,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 18th. The shares were bought at an average cost of $0.40 per share, for a total transaction of $750,000.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Timothy C. Dec purchased 65,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 18th. The shares were purchased at an average price of $0.40 per share, for a total transaction of $26,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 118,966 shares in the company, valued at approximately $47,586.40. The disclosure for this purchase can be found here. Corporate insiders own 53.27% of the company’s stock.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Want to see what other hedge funds are holding OPGN? Visit to get the latest 13F filings and insider trades for OpGen, Inc. (NASDAQ:OPGN).

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.